Literature DB >> 4467873

A studyof the pharmacokinetics of clidamycin in normal subjects and patients with chronic renal failure.

J B Eastwood, P E Gower.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1974        PMID： 4467873      PMCID： PMC2496026          DOI： 10.1136/pgmj.50.589.710

Source DB:  PubMed          Journal:  Postgrad Med J        ISSN： 0032-5473            Impact factor:   2.401


× No keyword cloud information.
  8 in total

1.  Microbiological and pharmacological behavior of 7-chlorolincomycin.

Authors:  B R Meyers; K Kaplan; L Weinstein
Journal:  Appl Microbiol       Date:  1969-05

2.  Septicaemia and pulmonary embolism complicating use of arteriovenous fistula in maintenance haemodialysis.

Authors:  J Levi; M Robson; J B Rosenfeld
Journal:  Lancet       Date:  1970-08-08       Impact factor: 79.321

3.  Clinical and bacteriological studies with clindamycin.

Authors:  A M Geddes; F A Bridgwater; D N Williams; J Oon; G J Grimshaw
Journal:  Br Med J       Date:  1970-06-20

4.  Absorption, excretion and half-life of clinimycin in normal adult males.

Authors:  J G Wagner; E Novak; N C Patel; C G Chidester; W L Lummis
Journal:  Am J Med Sci       Date:  1968-07       Impact factor: 2.378

5.  Maintenance haemodialysis.

Authors:  J R Curtis; J B Eastwood; E K Smith; J M Storey; P J Verroust; H E de Wardener; A J Wing; E M Wolfson
Journal:  Q J Med       Date:  1969-01

6.  Clinical uses and control of rifampicin and clindamycin.

Authors:  I Phillips
Journal:  J Clin Pathol       Date:  1971-07       Impact factor: 3.411

7.  Intermittent haemodialysis: insertion and care of the silastic-teflon cannula.

Authors:  G J Clunie; A M Martin; B Nolan
Journal:  Br Med J       Date:  1967-07-08

8.  Hemodialysis properties of clindamycin (7-chloro-7-deoxylincomycin).

Authors:  J E Cimino; P M Tierno
Journal:  Appl Microbiol       Date:  1969-03
  8 in total
  4 in total

1.  Pharmacokinetic variability of clindamycin and influence of rifampicin on clindamycin concentration in patients with bone and joint infections.

Authors:  Emmanuel Curis; Vincent Pestre; Vincent Jullien; Luc Eyrolle; Denis Archambeau; Philippe Morand; Laure Gatin; Matthieu Karoubi; Nicolas Pinar; Valérie Dumaine; Jean-Claude Nguyen Van; Antoine Babinet; Philippe Anract; Dominique Salmon
Journal:  Infection       Date:  2015-04-03       Impact factor: 3.553

2.  Protection from doxorubicin-induced nephrotoxicity by clindamycin: novel antioxidant, anti-inflammatory and anti-apoptotic roles.

Authors:  Kamilia M Ibrahim; Eman M Mantawy; Mona M Elanany; Hend S Abdelgawad; Nuha M Khalifa; Rada H Hussien; Nermeen N El-Agroudy; Ebtehal El-Demerdash
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2019-12-18       Impact factor: 3.000

Review 3.  Clinical pharmacokinetics of antibiotics in patients with impaired renal function.

Authors:  W L St Peter; K A Redic-Kill; C E Halstenson
Journal:  Clin Pharmacokinet       Date:  1992-03       Impact factor: 6.447

4.  Serum and plasma concentrations of clindamycin following a single intramuscular injection of clindamycin phosphate in maintenance haemodialysis patients and normal subjects.

Authors:  A P Roberts; J B Eastwood; P E Gower; C M Fenton; J R Curtis
Journal:  Eur J Clin Pharmacol       Date:  1978-12-18       Impact factor: 2.953
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.